Table 3. Chimerism and tumor responses... | American Society of Hematology

Table 3.

Chimerism and tumor responses of the 11 patients with hematologic malignancies treated with a sibling graft

Patient no.	Disease	Donor chimerism					Disease state at 8 wk	Survival days
Patient no.	Disease	Wk 1	Wk 2	Wk 3	Wk 4	Wk 8	Disease state at 8 wk	Survival days
1	Lymphoma	5%	0	0	0	0	CR	1285^3-150
2	Lymphoma	10%	10%	Not obtained	Patient died of progressive disease			28
6	Myeloma	0	0	Not obtained	100%	100%	CR	116
8	Myeloma	10%	10%	0	0	0	Stable	229
9	CML	0	0	67%	5%	5%	No response	129
11	Lymphoma	5%	Not obtained	Not obtained	Patient died of progressive disease			29
12	Lymphoma	10%	40%	90%	100%	100%	CR	222
20	Lymphoma	0	0	0	67%	Patient died of progressive disease		37
23	CLL	0	0	0	0	0	PR	179
24	Lymphoma	0	0	0	0	Patient died of progressive disease		40
25	AML	0	100%	100%	100%	100%	CR	630^3-150

Patient no.	Disease	Donor chimerism					Disease state at 8 wk	Survival days
Patient no.	Disease	Wk 1	Wk 2	Wk 3	Wk 4	Wk 8	Disease state at 8 wk	Survival days
1	Lymphoma	5%	0	0	0	0	CR	1285^3-150
2	Lymphoma	10%	10%	Not obtained	Patient died of progressive disease			28
6	Myeloma	0	0	Not obtained	100%	100%	CR	116
8	Myeloma	10%	10%	0	0	0	Stable	229
9	CML	0	0	67%	5%	5%	No response	129
11	Lymphoma	5%	Not obtained	Not obtained	Patient died of progressive disease			29
12	Lymphoma	10%	40%	90%	100%	100%	CR	222
20	Lymphoma	0	0	0	67%	Patient died of progressive disease		37
23	CLL	0	0	0	0	0	PR	179
24	Lymphoma	0	0	0	0	Patient died of progressive disease		40
25	AML	0	100%	100%	100%	100%	CR	630^3-150

CML indicates chronic myelogenous leukemia.

Patient alive at last follow-up of December 31, 2001.